(Q41382502)

30 September 2017

1 reference

title

The clinical pharmacokinetics of cladribine (English)

1 reference

30 September 2017

1 reference

Liliemark J

1

1 reference

30 September 2017

publication date

1 February 1997

1 reference

Clinical Pharmacokinetics

30 September 2017

published in

1 reference

30 September 2017

volume

32

1 reference

30 September 2017

issue

2

1 reference

30 September 2017

page(s)

120-131

1 reference

2-Chlorodeoxyadenosine dose escalation in nonhematologic malignancies

30 September 2017

cites work

1 reference

12 December 2020

Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies

1 reference

12 December 2020

Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of ?first-pass? metabolism

1 reference

12 December 2020

The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia

1 reference

12 December 2020

Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo

1 reference

12 December 2020

Relationship between pharmacokinetic parameters in patients and cytotoxicity in vitro of standard and investigational anticancer drugs

1 reference

12 December 2020

Cladribine in treatment of chronic progressive multiple sclerosis

1 reference

12 December 2020

Oral 2-chlorodeoxyadenosine in psoriatic arthritis. A preliminary report

1 reference

12 December 2020

A phase I clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia

1 reference

12 December 2020

Analysis of 2-chloro-2'-deoxyadenosine in human blood plasma and urine by high-performance liquid chromatography using solid-phase extraction

1 reference

12 December 2020

Determination of 2-chloro-2'-deoxyadenosine in human plasma

1 reference

12 December 2020

Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine

1 reference

12 December 2020

Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine.

1 reference

12 December 2020

Evidence that 2-chlorodeoxyadenosine in combination with cyclosporine prevents rejection after allogeneic small bowel transplantation

1 reference

12 December 2020

Quantitative prediction of drug toxicity in humans from toxicology in small and large animals

1 reference

12 December 2020

Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

1 reference

12 December 2020

Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy

1 reference

12 December 2020

Synthesis and biological activity of selected 2,6-disubstituted-(2-deoxy- -and- -D-erythro-pentofuranosyl)purines

1 reference

12 December 2020

On the paradoxically concentration-dependent metabolism of 6-mercaptopurine in WEHI-3b murine leukemia cells

1 reference

12 December 2020

Purine Analogs for the Treatment of Low-Grade Lymphoproliferative Disorders.

1 reference

12 December 2020

2-Chlorodeoxyadenosine (2-CdA): A Potent Chemotherapeutic and Immunosuppressive Nucleoside

1 reference

12 December 2020

Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth

1 reference

12 December 2020

Phosphorylation of 2-chlorodeoxyadenosine (CdA) in extracts of peripheral blood mononuclear cells of leukaemic patients

1 reference

12 December 2020

Substrate specificity of mitochondrial 2'-deoxyguanosine kinase. Efficient phosphorylation of 2-chlorodeoxyadenosine

1 reference

12 December 2020

The treatment of chronic progressive multiple sclerosis with cladribine

1 reference

12 December 2020

Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes

1 reference

12 December 2020

Cladribine (2-chlorodeoxyadenosine)

1 reference

12 December 2020

Pharmacologically guided phase I clinical trials based upon preclinical drug development

1 reference

12 December 2020

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration

1 reference

12 December 2020

Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia

1 reference

12 December 2020

Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy

1 reference

12 December 2020

Cellular pharmacokinetics of 2-chloro-2'-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients

1 reference

12 December 2020

Antileukemic and immunosuppressive activity of 2-chloro-2'-deoxyadenosine

1 reference

12 December 2020

On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humans

1 reference

12 December 2020

Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia

1 reference

12 December 2020

Pharmacokinetics of cladribine (2-chlorodeoxyadenosine) in children with acute leukemia.

1 reference

12 December 2020

Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs

1 reference

12 December 2020

Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma

1 reference

12 December 2020

Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.

1 reference

12 December 2020

Kinetics and metabolism of 2-chloro-2'-deoxyadenosine and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine in the isolated perfused rat liver

1 reference

12 December 2020

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

1 reference

12 December 2020

2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia

1 reference

12 December 2020

On the bioavailability of 2-chloro-2'-deoxyadenosine (CdA). The influence of food and omeprazole.

1 reference

12 December 2020

Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man.

1 reference

12 December 2020

2-Chlorodeoxyadenosine treatment of low-grade lymphomas

1 reference

12 December 2020

2-Chlorodeoxyadenosine Treatment of Refractory Chronic Lymphocytic Leukemia

1 reference

12 December 2020

Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity

1 reference

12 December 2020

Response of meningeal Waldenström's macroglobulinemia to 2-chlorodeoxyadenosine

1 reference

12 December 2020

Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice

1 reference

12 December 2020

Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions

1 reference

12 December 2020

The potential importance of soluble deoxynucleotidase activity in mediating deoxyadenosine toxicity in human lymphoblasts

1 reference

12 December 2020

Bioavailability and bacterial degradation of rectally administered 2-chloro-2'-deoxyadenosine.

1 reference

12 December 2020

2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma

1 reference

12 December 2020

10.2165/00003088-199732020-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

30 September 2017

1025823466

0 references

1 reference